Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema (bilateral)
ICD-10 E10.3513 is a billable code used to indicate a diagnosis of type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema (bilateral).
E10.3513 refers to a specific complication of Type 1 diabetes mellitus characterized by proliferative diabetic retinopathy (PDR) with bilateral macular edema. PDR is a severe form of diabetic retinopathy where new, abnormal blood vessels grow on the retina, which can lead to vision loss. The presence of macular edema indicates that fluid has accumulated in the macula, the central part of the retina responsible for sharp vision. This condition is often associated with poor glycemic control, typically reflected in elevated HbA1c levels, which indicate chronic hyperglycemia. Management of this condition often requires intensive insulin therapy and regular monitoring of blood glucose levels to maintain HbA1c within target ranges. Patients may also require interventions such as laser photocoagulation or intravitreal injections to manage the complications of retinopathy effectively. Regular eye examinations are crucial for early detection and treatment of diabetic eye diseases.
Detailed records of diabetes management, including insulin regimens and HbA1c levels.
Patients with poorly controlled diabetes presenting with eye complications.
Ensure documentation reflects the severity of diabetes and associated complications.
Comprehensive eye examination reports detailing findings of retinopathy and macular edema.
Patients undergoing treatment for diabetic retinopathy.
Document the specific type of retinopathy and treatment provided.
Used for treatment of proliferative diabetic retinopathy.
Document the indication for laser treatment and the extent of retinopathy.
Ophthalmologists should ensure that the procedure is linked to the diagnosis of E10.3513.
Coding E10.3513 accurately reflects the severity of diabetic retinopathy and macular edema in patients with Type 1 diabetes, which is essential for appropriate treatment and management.
Patients with E10.3513 should have regular eye examinations, typically every 6 to 12 months, and their HbA1c levels should be monitored quarterly to ensure effective diabetes management.
